MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

gildeuretinol acetate

  • Home
  • gildeuretinol acetate
Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: Insights from the TEASE-1 Randomized Clinical Trial
Posted inClinical Updates news Ophthalmology

Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: Insights from the TEASE-1 Randomized Clinical Trial

Posted by By MedXY 09/07/2026
This review synthesizes evidence from the TEASE-1 trial and related studies on gildeuretinol acetate, highlighting its safety profile and modest efficacy in slowing retinal atrophic lesion growth in Stargardt disease over 24 months.
Read More
  • Prognostic Value of Early ST2 and REG3α Measurements in Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide
  • Switching from Mepolizumab to Benralizumab in EGPA: A Promising Alternative for Persistent Respiratory Symptoms
  • Impact of 24-Hour Blood Pressure Variability on Retinal Nerve Fiber Layer Progression in Primary Open-Angle Glaucoma
  • Advancing Ear Disease Diagnosis: Optical Coherence Tomography Enables Quantitative, Point-of-Care Tympanic Membrane Imaging
  • Impact of Cholecystitis Treatment on Continuation of Cancer Therapy: Insights from a Decade-long Institutional Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top